Business
Vivani Medical to Participate in Panel Discussion at the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
EMERYVILLE, Calif.--(BUSINESS WIRE)-- Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), an innovative, near clinical-stage biopharmaceutical
About this update from Vivani Medical, Inc.
[{"type":"text","content":" EMERYVILLE, Calif.--(BUSINESS WIRE)--\nVivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), an innovative, near clinical-stage biopharmaceutical company that develops novel, miniature, long-term therapeutic implants, announced today that Company CEO Adam Mendelsohn, Ph.D. has been invited to participate at the Healthcare Virtual Conference Part II, presented by Maxim Group LLC and hosted by M-Vest. Dr. Mendelsohn will participate in the panel discussion entitled “Oh! Oh! Ozempic - Metabolics are in Focus” on June 20 at 11:00 am ET.\n\n\nThe exponential growth in knowledge and expertise in science and medicine continues to drive opportunities in the healthcare space. These include multiple therapeutic categories and emerging technologies, which Maxim’s presenting companies at this year’s Maxim Healthcare Conference are focused on, and for many, that includes key data-driven events in 2023. Maxim Senior Analysts will host a wide range of biotechnology and medical device companies in a series of presentations and interactive discussions with CEOs and key management. Maxim will also be hosting several topical industry panels that promise to be timely and engaging.\n\n\nThis conference, which takes place June 20-22, will be accessible live on M-Vest. To attend, please sign up to become an M-Vest member.\n\n\nClick Here to Reserve your seat\n\n\nAbout Vivani Medical, Inc.\n\n\nLeveraging its proprietary NanoPortal platform, Vivani Medical develops biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time, with the goal of guaranteeing patient adherence and potentially improving tolerability to their medication. Vivani’s lead program, NPM-119, is a miniature, 6-month GLP-1 implant under investigation for the treatment of patients with Type 2 diabetes and/or obesity. NPM-119 can provide patients the opportunity to realize the full potential benefit of their medication while avoiding the hassles associated with the daily or weekly administration of oral and injectable products. Medication non-adherence occurs when patients do not take their medication as prescribed. This affects an alarming number of patients, approximately 50%, including those taking daily pills. Medication non-adherence and poor tolerability are main reasons why Type 2 diabetes and/or obesity treatments face chall...